Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Investors were not convinced by Vertex’s bullish outlook on its data, with the company’s stock falling by 15.53% compared to ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

This comprehensive analysis examines Vertex's current position ... You can also see if VRTX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of ...

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

This comprehensive analysis examines Vertex's current position ... You can also see if VRTX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of investment ...